All News

“We saw in the survey that men are concerned with how the health decisions they make now will affect them in the future,” says Petar Bajic, MD.

“Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival,” says Solomon Woldu, MD.

YOLT-203 is currently being assessed in the early phase 1 YOLT-203-101 trial.

Olaparib plus abiraterone and prednisone or prednisolone was granted FDA approval in May 2023 for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated mCRPC.

Patients who had mutations in the ERCC2, ATM, or RB1 genes were more than 5 times more likely to achieve a pathologic complete response following cisplatin-based chemotherapy.

Treatment with an ARPI extended overall survival (OS), with a median OS of 38.7 months in the ARPI arm vs 21.7 months in the taxane arm and 21.8 months in the physician’s choice of treatment arm.

Data indicated that the test preferentially detected high-grade, clinically significant prostate cancer, with 93% of detected cancers being GG3-5 and 67% being stage 3 or 4.

In total, 8 of 40 patients who underwent ultrasonic propulsion experienced relapse, compared with 21 of 42 patients who underwent observation.

"A surprise finding was the increase in opioid fulfillment beyond the 7-day postoperative period, which was really unexpected," says Laura Gressler, MS, PhD.

The approval is based on findings from the first interim analysis of the phase 3 EV-302 trial.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.

The phase 3 trial will assess the anti-tumor activity of 9MW2821 plus toripalimab vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

"Generative AI technologies may play a valuable role in providing prompt, accurate responses to routine patient questions––potentially alleviating patients' concerns while freeing up clinic time and resources to address other complex tasks," says Michael Scott, MD.

In total, the trial plans to enroll 7 patients with PH1 through a single center in China.

The approval is supported by data from cohort 1 of the phase 3 THOR trial.

"Donor-advised funds are a fast-growing charitable giving vehicle in the US because they are one of the easiest and most tax-advantageous ways to give to charity," writes Jeff Witz, CFP.

The approval is supported by findings from the phase 3 EV-302 trial.

“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.

The fast track designation for 64Cu-SAR-bisPSMA is supported by findings from Clarity’s ongoing clinical program for the imaging agent.

“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.

Any stone fragmentation was achieved in 88% of patients.

A full market release of the HYDROS System is expected within the current quarter.

"Early-career physicians should ask themselves whether they really need to purchase a home right away or whether they would be better served renting for a few years," writes Jeff Witz, CFP.

"Overall, we found that patients with recurrent RCC following adjuvant IO continued to have responses to different types of first-line systemic therapy," says Talal El Zarif, MD.

The approval for enfortumab vedotin is supported by findings from the global phase 3 EV-301 trial and the phase 2 EV-203 bridging trial in Chinese patients.

"The great news is that we have now completed recruitment. We actually recruited more than 1700 patients," says Kari A.O. Tikkinen, MD, PhD.

The phase 1 trial is assessing the safety and tolerability of MOMA-313 as both a monotherapy and in combination with olaparib in patients with HR-deficient advanced or metastatic solid tumors.